Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

Francesco Fanfani, Gabriella Ferrandina, Giacomo Corrado, Anna Fagotti, Haim Vito Zakut, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journalArticle

Abstract

Objectives: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery. Methods: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS. Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy. Results: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001). On the other hand, in the group of patients that underwent successful IDS, no differences in survival outcomes were observed between patients with no residual disease and patients with macroscopic residual disease

Original languageEnglish
Pages (from-to)316-322
Number of pages7
JournalOncology
Volume65
Issue number4
DOIs
Publication statusPublished - 2003

    Fingerprint

Keywords

  • Advanced stage
  • Interval debulking surgery
  • Neoadjuvant chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this